Ovarian Cancer Pipeline constitutes 180+ key companies continuously working towards developing 200+ Ovarian Cancer treatment therapies, analyzes DelveInsight.
Ovarian Cancer Overview:
Ovarian cancer is the deadliest gynecological cancer and the fifth leading cause of death among women overall. Late-stage diagnosis is common, resulting in poor outcomes. Current screening methods, including cancer antigen-125 (CA-125) assays, have limited effectiveness in reducing morbidity or mortality.
Epithelial ovarian cancer is the most common form, with four main histological types: serous, endometrioid, clear cell, and mucinous tumors, as well as rarer types like Brenner and seromucinous tumors. Based on biology and prognosis, ovarian cancer is classified into two subtypes:
- Type I tumors: Include low-grade serous, endometrioid, clear cell, mucinous, Brenner, and seromucinous carcinomas. They generally originate from borderline tumors, are detected early, and have a favorable prognosis. These tumors exhibit low proliferative activity and minimal genetic instability.
- Type II tumors: Include high-grade serous carcinoma, carcinosarcoma, and undifferentiated carcinoma. They arise from serous tubal intraepithelial carcinoma, are typically aggressive, high-grade, and diagnosed at advanced stages. They show rapid progression, significant chromosomal instability, and frequent mutations in the p53 gene.
Type II tumors are more aggressive and lethal than Type I, highlighting the need for improved early detection and treatment strategies.
Request for a detailed insights report on Ovarian Cancer pipeline insights @ https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Ovarian Cancer Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Ovarian Cancer Therapeutics Market.
Key Takeaways from the Ovarian Cancer Pipeline Report
-
DelveInsight’s Ovarian Cancer pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Ovarian Cancer treatment.
-
In May 2025, Allarity Therapeutics concluded a Phase II trial for stenoparib (2X-121) after observing significant clinical benefits in earlier trial phases. The company now aims to launch a follow-up trial designed to expedite regulatory submission for stenoparib.
-
Key Ovarian Cancer companies such as Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, and others are evaluating new drugs for Ovarian Cancer to improve the treatment landscape.
-
Promising Ovarian Cancer pipeline therapies in various stages of development include Atezolizumab, Tisotumab, SON-1010, DS-6000a, and others.
Ovarian Cancer Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Ovarian Cancer Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ovarian Cancer treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Ovarian Cancer market.
Download our free sample page report on Ovarian Cancer pipeline insights
Ovarian Cancer Emerging Drugs
-
Atezolizumab: Genentech
-
Tisotumab Vedotin: Genmab
-
SON-1010: Sonnet Biotherapeutics
-
DS-6000a: Daiichi Sankyo Company
Ovarian Cancer Companies
Over 180 major companies are actively developing therapies for ovarian cancer. Among them, Genentech stands out with its drug candidates in the most advanced stage of development, Phase III.
DelveInsight’s report covers around 200+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Ovarian Cancer Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Ovarian Cancer Therapies and Key Companies: Ovarian Cancer Clinical Trials and advancements
Ovarian Cancer Pipeline Therapeutic Assessment
• Ovarian Cancer Assessment by Product Type
• Ovarian Cancer By Stage
• Ovarian Cancer Assessment by Route of Administration
• Ovarian Cancer Assessment by Molecule Type
Download Ovarian Cancer Sample report to know in detail about the Ovarian Cancer treatment market @ Ovarian Cancer Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Ovarian Cancer Current Treatment Patterns
4. Ovarian Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Ovarian Cancer Late-Stage Products (Phase-III)
7. Ovarian Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Ovarian Cancer Discontinued Products
13. Ovarian Cancer Product Profiles
14. Ovarian Cancer Key Companies
15. Ovarian Cancer Key Products
16. Dormant and Discontinued Products
17. Ovarian Cancer Unmet Needs
18. Ovarian Cancer Future Perspectives
19. Ovarian Cancer Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Ovarian Cancer Pipeline Reports Offerings
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
